RESEARCH PAPER

Application of Artificial Intelligence and Computational Models in Anatomical Research for Targeted Drug Delivery Systems and Surgical-Assisted Therapeutic Applications

Dr. Shweta Borad[1*], Durga Prasad Mudrakola[2], Dr. Bhasha Anjaria[3], Trivedi Khushboo Nirajkumar[4], Keyaben Sanket Kumar Patel[5], Dr Kumar Sambhav[6]

[1*]Assistant Professor in Anatomy department, Doctor of Medicine -MD in Homoeopathy, Jay Jalaram Homoeopathic Medical College & Hospital, Morva, Rena, Panchmahal, Gujarat-389002, Email Id: boradshweta1995@gmail.com, Orcid Id: 0009-0002-3724-4415

[2]Dean, School of Dental Sciences and Technology, Specialization in Periodontics, Malla Reddy Vishwavidyapeeth, Telangana, Hyderabad – 500055, Email Id: drdurgaprasad31@gmail.com

[3]Assistant Professor, Department of CSE, Parul University Vadodara, Gujarat, India, Email Id: bhasha.anjaria21316@paruluniversity.ac.in, Orcid Id: 0000-0002-0562-4336

[4]Assistant Professor, Department of Computer Science And Engineering, Specialization in ML, DL , AI, Parul University Vadodara, Gujarat, India, Email Id: khushboo.trivedi21305@paruluniversity.ac.in, Orcid Id: 0009-0008-3197-4234

[5]Assistant Professor, Department of Computer Science and Engineering, Specialization in AI & ML, Parul University Vadodara, Gujarat, Email Id: keyaben.patel17883@paruluniversity.ac.in, Orcid Id: 0000-0003-2058-8289

[6]Assistant Professor, Department of Anatomy, MD(Anatomy), All India Institute of Medical Sciences, Bilaspur, Himachal Pradesh, Email Id: drkrsambhavaiims@gmail.com, Orcid Id: 0000-0003-0012-3994

Abstract

The newest developments in drug delivery science have shifted the development of therapeutic approaches towards precision-oriented and patient-specific approaches which consider anatomical, physiological, and pathological variability. Targeted drug delivery systems seek to find a balance between controlled localization and release of therapeutic reagents and reduced systemic exposure, although their design is not easy due to the multiscale nature of the bio-environment. Computational modelling and artificial intelligence have become effective means of solving these issues by allowing the analysis of the data, predictive simulation, and rational optimization of the methods of delivery. This review will focus on the use of artificial intelligence and computational models in anatomical studies to facilitate the creation of targeted drug delivery systems, surgical-assisted therapeutic systems. The application of machine learning in combination with anatomical data obtained by imaging, physiologically realistic pharmacokinetic modelling, computational fluid dynamics, and molecular dynamics simulation is presented in the context of nanoparticle-based delivery vehicles, smart and stimuli-responsive systems, and localized delivery devices. The review also emphasizes the advantages of image-guided and surgical-assisted methods, which are enhanced in computational intelligence to serve as better in terms of spatial accuracy, control of therapies, and customization. The existing constraints associated with data access, the applicability of the model, and regulatory aspects are also discussed and the new possible trends toward an adaptive and anatomy-inspired delivery platform. In general, the intersection of artificial intelligence, computational modelling, and anatomical understanding is a paradigm-shifting model of future drug delivery technologies and precision therapeutics.

Keywords: Artificial Intelligence, Targeted Drug Delivery, Computational Modelling, Anatomical Research, Image-Guided Therapy

How to cite this article: Borad S, Mudrakola DP, Anjaria B, Nirajkumar TK, Patel KSK, Sambhav K. Application of Artificial Intelligence and Computational Models in Anatomical Research for Targeted Drug Delivery Systems and Surgical-Assisted Therapeutic Applications. Int J Drug Deliv Technol. 2026;16(18s): 387-400. DOI: 10.25258/ijddt.16.18s.41

1. Introduction

The drug delivery science has transformed tremendously over the past decade, but the conventional dosage regimens are substituted with precise and patient-centred treatment regimes. This has been promoted by the continuously increasing complexity of disease biology, diversity in anatomy of patients and increased use of increased therapeutic efficacy and decreased systemic toxicity. In this respect, targeted delivery has acquired the form of drug delivery systems to become a pillar of modern pharmaceutics, that is, spatial and temporal control of drug releases and biodistribution. AI is a somewhat new field as a facilitating technology that can be disruptive to defeat the multidimensionality of a sophisticated drug delivery design and optimization.

The increasing artificial intelligence in smart drug delivery systems has shown good potential in the area of personalized medicine through optimizing the carrier options, release patterns and treatment responses with the assistance of data-driven decision-making systems[1]. There is a tendency to apply AI-based systems to predict the performance of the formulation, increase efficiency and minimize the delivery strategy based on the specific patient profile. All these skills are particularly applicable

*Author for Correspondence: boradshweta1995@gmail.com

in the particular delivery in which there is an interplay of the anatomical, physiological and pathological parameters to ascertain the success of the therapy.

One of the most pressing AI uses in drug delivery is to enhance the efficacy of nanoparticle-based delivery particularly in cancer treatment, where the anatomy and tumour heterogeneity present challenges in drug concentration in the disease location. Machine-learning-based analyses are helpful in validation of nanoparticles efficiency in the delivery to tumor tissue enabling prediction of biodistribution and target specificity[2]. The above strategies show the greater importance of computational intelligence in the gap between the formulation design and the in vivo performance.

The development and testing of excellent drug delivery systems entail adequate characterization plans that provoke structural and functional attributes of delivery platforms. General techniques of characterization remain the most important tools in evaluating particle size, morphology, surface properties, and release kinetics, which are successively used to characterize the efficacy of delivery[3]. However, the complexity of the new delivery systems is not typically controllable through traditional experimental methods and there is need to introduce the use of computational and data-driven methods.

Even such experimental studies on nanoparticles as the targeted drug delivery vehicle still provide important information about the behavior of the processes of formulation and release in in vitro conditions[4]. These experimental data form the foundation on which the computing models and AI algorithms may be trained, validated and refined. Integrating experimental pharmaceutics and computational intelligence will permit even more predictive and vigorous drug delivery design paradigm.

The more sophisticated methods of computation that combine machine learning and molecular dynamics simulations have contributed to the understanding of the interactions of drugs and carriers at both the molecular and nanoscale. Through the assistance of these hybrid approaches, stability, encapsulation efficiency and release behavior of nanoparticle systems can be predicted and therefore can be designed to accelerate the rational design of delivery systems[5]. These tools would come in handy, particularly in the case of customisation of delivery platforms into specific anatomical environments.

Computational and chemometric modelling techniques have also been shown to be helpful in the design of site-delivery systems such as polysaccharide-coated formulations to deliver drugs in the colon. The techniques use anatomical and physiological parameters in predictive models and hence fine control of the drug delivery profiles in particular regions of the gastrointestinal tract[6]. This shows the growing concern of anatomy-based computational modelling to target pharmaceutics.

Machine-learning-based spectroscopic analysis of samples has proven useful in the prediction of drug release properties in coated delivery systems, and enables the non-destructive and real-time analysis of formulation performance[7]. These techniques are quite consistent with the objectives of a controlled and targeted drug delivery where a high level of control of the release kinetics is achieved without much trial and error in the experiments.

Kinetics of drug release Statistical and computational modeling of the drug release kinetics is a subtopic of optimization of transport systems, particularly in the case of polymeric carriers in the form of nanoparticles of such a type as PLGA. Kinetic models are beneficial to study knowledge through comparative models of interaction and rational selection of delivery platforms[8]. The models are the intermediators between experimental and prediction computational prediction structures.

Microfluidic technologies have similarly enhanced nanoparticle systems tunable whereby the size/distribution of particles is specifically controlled as a significant determinant of targeting to anatomy and biodistribution[9]. These manufacturing approaches are confirmed by scalable and repeatable production of highly sophisticated drug delivery systems on the condition of AIs-controlled optimization.

Besides the conventional delivery systems, the use of artificial intelligence on nanobionic and hybrid therapeutic systems has extended the pharmacokinetic and pharmacodynamic delivery functions of nanoparticle delivery systems in both multifunctional and anatomical responsive delivery applications. The AI-based nanobionic systems offer the prospects of the targeted therapy, predictive toxicity, and surgical-assisted therapeutic intervention, which facilitates the translational opportunities of the intelligent drug delivery technologies[10]. This review aimed:

- To critically examine how artificial intelligence and computational modeling integrated with anatomical research, enhance the design, optimization, and prediction of targeted drug delivery systems.
- To evaluate the role of AI-enabled imaging and surgical-assisted strategies in improving spatial precision, therapeutic control, and translational potential of advanced drug delivery technologies.

2. Role of Anatomical Research in Targeted Drug Delivery

2.1 Anatomical Determinants of Drug Distribution

The anatomical features are factors that are decisive in the fate of drug delivery systems after it has been administered, especially on targeted and controlled drug delivery platforms. Directive influences on nanoparticle penetration, retention and release behavior include tissue architecture, cellular density, extracellular matrix composition, and interstitial space spacing. Drug delivery is also controlled by vascular changes in vascular organization and perfusion that influence carrier extravasation and systemic clearance, and so anatomical factors play a critical role in the optimal design of delivery systems. Such analyses based on

artificial intelligence have been used to combine anatomical and physiological variables into predictive models to facilitate personalized design of drug delivery[11].

One of the anatomical challenges associated with targeted delivery is the biological barriers. Selective permeability restrictions of the blood-brain barrier, tumor stroma, mucosal epithelium and endothelial tight junctions restrict access of drugs to target sites. State-of-the-art models utilizing both anatomical and physiologically-founded models of pharmacokinetics allow to predict the interaction of the barriers and transport constraints of the various delivery routes[12]. Computational strategies based on such anatomy help to increase the rational choice of the delivery systems that will be able to overcome these obstacles.

Anatomical variability between patients also makes the distribution of drugs more difficult as organs may differ in size, vascular density, and pathological remodeling with this variability potentially dramatically affecting the results of therapy, as illustrated in Table 1. The use of AI in drug delivery models sees a growing trend of using anatomically specific parameters to enhance the accuracy of targeting and accuracy of dosing, citing the significance of anatomical studies in contemporary pharmaceutics[13].

Table 1: Imaging-Guided Anatomical Platforms Supporting Targeted Drug Delivery

Anatomical focus	Delivery platform	AI/modelling role	Imaging guidance	Reference
Tumor tissue	CT-contrast nanomaterials	Dose optimization	CT imaging	[14]
Vascular / organ regions	Predictive nanocarriers	AI-driven design	Multimodal imaging	[15]
Local tissue site	PLGA implant	Release modeling	Image-guided placement	[16]
Renal tumor	Lipid nanoparticles	Target selection	Imaging-assisted delivery	[17]
Solid tumor	Liposomes	Carrier optimization	Image-guided therapy	[18]

2.2 Imaging-Based Anatomical Mapping

The evolution of medical imaging technologies provides the necessary background to the anatomical investigations in terms of targeted drug therapy since it allows to visualize tissues, organs and pathological regions (non-invasive). Some of the modalities would include magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, and optical imaging that are used to provide complementary anatomical and functional information to be used in developing the design of the delivery system. Image guided techniques have been particularly effective in the oncology field whereby good localization of tumours and the surrounding tissues is the determinant of successful therapeutic targeting. It has been demonstrated that nanotheranostic systems can incorporate diagnostic imaging and drug delivery on the same platform using anatomical real-time guidance and drug therapy monitoring[19].

The importance of MRI in the mapping of the anatomy is that it has high spatial resolution, soft tissue contrast, which is necessary in the determination of carrier biodistribution and target accumulation. The delivery of drug MRI-based polymeric nanocarriers can track the delivery routes and simultaneously deliver therapeutic nucleic acid molecules to the target anatomy, thereby enhancing anatomy targeting. The application of fluorescent imaging and MRI deepens the insight into the anatomy since the molecular sensitivity is combined with structural data which assists in the process of assessment of the drug delivery mechanisms at the multiscale level.

Anatomic models produced by these modalities and produced as an image are getting used more often as input to computational models and AI-based optimization of drug delivery plans. The models permit the efficacy of patient-specific planning of focusing delivery tracks, dosages and release profiles that improve the translational capacity of anatomically informed pharmaceutics, such as in Figure 1.



Figure 1: Imaging-Based Anatomical Mapping for Targeted Drug Delivery Design

2.3 Challenges in Translating Anatomy to Delivery Design

Despite all the marvellous advances in the sphere of anatomical imaging and modelling, it is difficult to apply the anatomical knowledge, to the effective design of drug delivery. The major constraint lies in the fact that the anatomical systems undergo dynamic changes of both physiological and pathological changes that constantly affect the transport and release of drugs. The changes may arise due to anatomical conditions due to the presence of tumours, inflammation, vascular remodelling, and post-surgical alterations, and therefore to design fixed delivery. Artificial intelligence (AI) based adaptive models are also considered to solve this change of time and update predictions based on the changing state of the anatomical conditions[20].

The second barrier is the complexity of drug delivery which is multiscale where molecular, cellular, tissue, and organ interactions occur. The information that is taken about anatomies at the macroscopic scale may not necessarily be entirely representative of the phenomena of transport at the microscale that govern carrier uptake and release. Physiological based pharmacokinetic approaches and first principles modelling provide systematic means of scaling anatomical characteristics though their union is computationally prohibitive[21]. The difference in these scales is needed in the establishment of foreseeable performance of delivery.

In addition, the standardization of the imaging resolution, segmentation quality, and the data of the models used to deliver anatomy might have low credibility. Despite the possible solutions of nanotheranostic systems that relate to the integration of imaging and therapy, their clinical use must be carefully validated and aligned with regulatory requirements. These are major problems that must be contended with to bring out the full potential of the anatomical research in drug delivery systems design.

3. Artificial Intelligence in Drug Delivery System Design

3.1 Machine Learning Techniques Used in Drug Delivery

The latter has predisposed the use of machine learning as a crucial component of designing and optimization of advanced drug delivery systems due to the ability to work with multidimensional and complex data. Supervised learning models are frequently applied to the problem of pharmaceutics, where the relations between formulation conditions and delivery outcomes are required (e.g. encapsulation efficiency, release rate, and therapeutic efficacy). The models are modeled on labeled experimental information and are utilized in predicting the performance of the system and deployed in refining formulation. The unsupervised types of learning like clustering and dimensionality reduction are also gaining popularity as the techniques of identifying the concealed patterns in the formulation datasets that enables the classification of delivery systems, based on physicochemical and biological characteristics.

The reinforcement learning approaches are also becoming interested in adaptive drug delivery design where parameters of drug delivery are optimised by a learning algorithm based on feedback to optimise the drug delivery as depicted in Figure 2. More recent deep learning architectures, including convolutional neural networks, transformer-based architectures, make the predictions more accurate, as they learn more nonlinear relationships between the manipulation variables and the biological response. These AI-based methods prove particularly useful in the delivery of images-based methods where the spatial and the temporal information should be read simultaneously. Image-guided control and tracking of polydopamine-based radio immunotherapeutic systems, image-guided optimization of systems, and therapeutic feedback has shown that machine learning is useful in improving the optimization of controlled releases and therapeutic monitoring of the delivery system design[22]. Overall, machine learning enables reducing the adoption of the development of data-driven and predictable drug delivery engineering

instead of trial and error in the process of coming up with the development.



Figure 2: Machine Learning Frameworks Supporting the Design and Optimization of Drug Delivery Systems.

3.2 AI-Driven Optimization of Drug Carriers

Artificial intelligence helps to make maximum of the drug carrier properties that directly influence the targeting efficiency and therapeutic performance. The size, shape, surface charge and surface functionalization of the nanoparticles are some of the parameters that significantly affect biodistribution, uptake and clearance by the cells. Such multidimensional design variables may be evaluated in speed by AI models to identify the optimal carrier settings to apply in specific anatomical and pathological targets. There is increased use of deep learning models that predict the effect of carrier modification on behavior in vivo that reduces the weight of experiments.

The application of AI in optimization to ligand selection as a mechanism towards targeted drug delivery is another area where there have been major changes. The patterns of receptor expression and molecular descriptors are applied to machine learning systems to find the largest specificity of the ligand and carrier interactions. Furthermore, the AI-based models are applied to study the efficiency of the loading technique and release kinetics and predict them through the experiment and simulation data. These abilities are especially relevant to nanomedicine systems that have built-in imaging features since the efficiency of delivery is supposed to be measured in real-time. Near-infrared II fluorescence images have made it possible to monitor the efficiency of delivery of nanomedicine with high level of precision which provides data of high quality which can be utilized to optimize the use of carriers by AI guidance[23].

The AI-experimental feedback will render the drug carrier design more efficient, reproducible, and anatomy-down-to-the-point.

3.3 AI in Predicting Pharmacokinetics and Biodistribution

One of the most complicated issues in targeted drug delivery is the process of predicting pharmacokinetics and biodistribution since therapeutic response is determined by dynamic interactions between the delivery system and biologic environments. Artificial intelligence has become an effective method to model absorption, distribution, metabolism, and elimination processes based on the combination of the properties of formulations and physiological and anatomical data. The nonlinear relationships that are hard to elucidate through standard pharmacokinetic methods can be determined by AI-based models and, therefore, enhance prediction accuracy.

Machine learning schemes are being used more and more to predict organ-specific accumulation and clearance profiles to provide insight into the rational design of delivery systems with better targeting capabilities. Such predictive models are especially useful in multifunctional nanoplatforms where therapy and imaging are combined as they can be used to simultaneously measure the performance of drug delivery and spatial localization of therapeutic actions[24].

Another possible use of patient-specific delivery optimization is an extension of AI-based pharmacokinetic modelling, as anatomical and physiological variability in individual patients largely affects drug fate. Image-based pharmacotherapy regimens also contribute to this kind of personalization by allowing customized therapies via predictive and actual biodistribution profiles[25], also in Table 2. The incorporation of AI-based prediction into the clinical imaging procedures enhances the translational effects of targeted drug delivery systems[26].

Table 2: AI-Enabled Prediction of Pharmacokinetics and Biodistribution in Targeted Drug Delivery

Modeling focus	Data input	AI / computational role	Delivery relevance	Reference

Image-guided procedures	Multimodal imaging	PK–biodistribution correlation	Spatial drug localization	27
Cancer nanotherapy	Nanoparticle descriptors	Target accumulation prediction	Tumor-specific delivery	28
Intravascular delivery	Hemodynamics + anatomy	Multiscale PK simulation	Circulation-driven transport	29
Lipid nanoparticles	In vitro PK/tox data	Potency–toxicity prediction	Safe systemic delivery	30
Thermal ablation	MR-guided anatomy	Distribution–thermal response	Localized drug activation	31

4. Computational Models Supporting Targeted Drug Delivery

4.1 Physiologically Based Pharmacokinetic (PBPK) Models

On the basis of anatomical and physiological parameter integration, physiological PBPK models provide a mechanistic method of prediction of drug absorption, distribution, metabolism and elimination. The models are also based on organ volumes, blood flow, tissue composition, and permeability which are used to model the movement of drugs across biological barriers. PBPK models find particular application in targeted drug delivery in examining the effects of anatomical constraints in maximising the delivery efficiency at a specific site e.g. the brain or tumours. The magnetic resonance devices of targeted ultrasound have revealed the relevance of the anatomical precision in the transient blood-brain barrier fissure opening, and this shows that anatomy-based PBPK modeling is relevant to the pharmaceutical delivery to the central nervous system[32].

PBPK methods can be used to simulate a population where anatomy and physiological variations between groups of patients exist and optimisation of dosing and risks can then be optimised. Patient specific models/adaptations are also being enriched with these models whereby imaging based anatomical information can be used to predict drug exposure in a unique way. There are also image-guided systems of delivering therapy which can be localized therapeutic eluters which have the benefit of PBPK modelling to determine spatial prediction of the drug distribution post-delivery[33].

Co-existence of PBPK models, imaging, and experimental data enhances predictability of the model and allow making a decision at the translation level. PBPK is a conceptual paradigm of rational design and clinical optimization of target drug delivery systems through filling the gap between formulation properties and anatomy (Figure 3).



Figure 3: Physiologically Based Pharmacokinetic (PBPK) Modeling Framework for Targeted Drug Delivery

4.2 Computational Fluid Dynamics (CFD)

One of the critical stages in drug transport and intravascular delivery behaviour study is the

computational fluid dynamics (CFD) modelling, which is mediated by the blood flow. Following a complicated vascular linger, CFD simulations allow measuring fluid flow, shear stress, and particle tracks, all of which are necessary to forecast nanocarrier distribution following systemic inoculation. CFD modelling CFD modelling has been applied to optimise the delivery parameters of the image-guided and minimally invasive delivery systems by simulating the behaviour of the delivery apparatus and tissue during delivery in the presence of flowing biological fluids. The study on needle tissue interaction and steering mechanism focus on the fact that an accurate inherent mechanical and fluidic modelling of needle-tissue interaction is crucial in deriving the correct outcomes regarding intravascular and local delivery of drugs[34].

CFD models have also been widely used in the analysis of aerosol transport in pulmonary delivery and the margination of nanoparticles in blood vessels flow, are two well-researched examples where flow behaviour is a leading factor in defining the targeting efficiency. These computer simulations allow the researcher to experiment the size of carrier, their shape and injection velocity on deposition and retention at anatomical targets. Oncology In Oncology CFD-based model has been found to be helpful in the design of delivery schemes which can be deployed to navigate through complex tumor vasculature and heterogenous perfusion conditions[35].

CFDs combined with anatomy and material properties can be applied to give predictive assessment of the performance of delivery under physiological realistic conditions as shown in Figure 4. The methodology enhances the rational design of a particular drug delivery platform and it reduces excessive reliance on the in vivo testing.



Figure 4: Computational Fluid Dynamics (CFD) Modeling of Drug Transport and Nanocarrier Behavior in Targeted Drug Delivery

4.3 Molecular Dynamics and Multiscale Modelling

Molecular dynamics (MD) and multiscale modelling techniques are used to give detailed information about drug carrier interactions and release mechanisms, on a molecular and mesoscopic scale. The MD simulations model drug-carrier and drug-biological media interactions at the atomic scale, which allows the determination of encapsulation stability, binding affinity, and release. These simulations are especially applicable to the nanocarrier-based systems of delivery, the performance of which is determined by molecular interactions. Multiscale modelling is becoming more and more important to sustainable nanotechnology frameworks coupled with artificial intelligence to bridge the gap between molecular behaviour and macroscopic therapeutic responses in image-guided delivery platforms[36].

Multiscale modelling is an intermediate among molecular dynamics, continuum-scale simulations, enabling the combination of nanoscale release processes with the transport of tissues and organs. This hierarchical method is mandatory in the correct prediction of the molecular interactions into biodistribution and therapeutic efficacy. Multiscale models can be used in focused ultrasound triggered delivery systems to assess carrier response to external stimuli taking into consideration anatomical constraints[37].

Collectively, a combination of molecular dynamics and multiscale modelling will offer a comprehensive computational basis towards specific drug delivery design. These models will be useful in the design of specific, responsive, and clinically translatable drug delivery technologies, by connecting molecular behavior with anatomical and physiological systems (Table 3).

Table 3: Computational Modeling Frameworks Supporting Targeted Drug Delivery Design

Model level	Core method	Key input	Predicted outcome	Delivery relevance	References
Translational modeling	In silico → clinical	Formulation + anatomy	PK performance	Bench-to-bedside DDS	[38]

Release modeling	Hybrid kinetic models	Polymer + drug data	Release profile	Controlled delivery	[39]
Nanocarrier modeling	Physicochemical simulation	Particle properties	Stability & transport	Nanoparticle DDS	[40]
Image-guided modeling	Deep learning	Real-time imaging	Spatial delivery accuracy	Localized delivery	[41]
Mathematical modeling	PDE-based simulation	Tissue–pathogen dynamics	Drug diffusion response	Surgical delivery context	[42]
Smart DDS modeling	Integrated AI frameworks	Multi-scale data	Adaptive release	Next-gen DDS	[43]

5. Integration of AI with Anatomical Modelling

5.1 AI-Enhanced Medical Image Segmentation

The design of targeted drug delivery requires proper anatomical segmentation in that it enables the accurate location of organs, tissue and pathological regions that can be targeted during the therapeutic process of targeting. The former is the sphere of artificial intelligence, namely, of the segmentation model of the image through deep learning, which has contributed to the accuracy of the model and its efficiency in delineating organs and tissues automatically based on the results of medical imaging in a form of MRI, CT, and PET in particular. The AI-based segmentation models allow consistent and repeatable anatomical mapping that is crucial in designing the delivery system and performance prediction. Proper location of the tumor boundaries and zone targeting in drug delivery research directly influence localization of the carrier, dose distribution and kinetics of release. The analysis of the image through AI can also offer the possibility to stratify the group of vulnerable patients considering anatomical and physiological deviations that affect the reaction to drugs and their interactions. The ability to forecast drug-drug interactions better and safer and anatomy-guided design of therapy in complex patient populations is further strengthened by integrating AI based anatomical segmentation into pharmacological workflows[44].

5.2 Digital Twins for Drug Delivery Planning

Digital twins represent a novel application of AI-enabled anatomical modelling, whereby it is possible to generate virtual simulations of organs or entire physiological systems, which are patient-specific. These computational models are a fusion of imaging-acquired anatomy and physiological, pharmacokinetic, and formulation-specific data with which to model the impact of drug delivery in diverse circumstances. Digital twins are useful in simulating dose distribution and carrier transport together with release behaviour in personalised anatomical models. With the help of such models, one can optimize a delivery strategy before clinical implementation and reduce uncertainty and improve precision in the therapeutic process. Regulatory science AI-based digital twins can generate new evidence generation, risk, and decision support opportunities across the drug lifecycle as a regulatory science. Their adoption too poses problems related to validation, transparency and acceptance by the regulator. An overview of the integration of AI-based digital twins in the pharmaceutical industry can be aligned with the transformation of the regulatory environment in favour of the development of models to guide the development of additional medications, although their safety, reproducibility, and ethical use of the newest computational models are guaranteed[45].

5.3 Predictive Modelling for Target Localization

The anatomy-directed drug delivery systems must have a predictive modelling of localizing the target, especially when there is a high level of localization required, such as in the case of therapies. Through the assistance of maximizing the spatial patterns applied in multimodal imaging and anatomical information to instruct the target, AI permits the automatic identification of the target. The models allow one to identify optimal sites of delivery, carrier accumulation and off-build-up evaluation of off-target exposures. The use of artificial intelligence predictive models has been useful in anatoms that are dynamic, such as the provision of the appropriate dose in situations whereby the organ motions, deformation or disease conditions can result in poor delivery outcomes. In the given instance, the theocentric means of delivery may be deployed with the help of the AI-based tracking models which will allow the principal to update the position of the targets (Figure 5). The downstream drug development phases including predictive target localization have also been employed to provide data on screening, design and clinical trials planning of the delivery-dependent therapeutics. The integration of the anatomical intelligence and pharmacological modelling can be used to optimize the prediction of the AI and is thus applicable to maximize the achievement of the target drug delivery systems and the translation process between the preclinical design and the clinical implementation[46].



Figure 5. AI-Based Predictive Modelling Framework for Target Localization in Anatomy-Driven Drug Delivery

6. Targeted Drug Delivery Systems Enabled by AI and Computational Tools

6.1 Nanoparticle-Based Targeted Delivery

The liposomes and polymeric nanoparticles and lipid nanoparticles are the building blocks of the current targeted drug delivery due to their ability to control physicochemical properties and improved therapeutic index. Nanocarrier design is highly optimized through the artificial intelligence since it enables optimization of size, surface chemistry, drug loading and targeting ligands to be optimized based on data. To make the discovery of the best nanocarrier systems, nanocarrier-based models using AI allow the simultaneous discovery of the formulation parameters and the biological performance of drugs. These techniques reduce the amount of work in experiments and increase the addition of pharmacokinetics and biodistribution. Preclinical formulation screening translation into clinical dose selection with the assistance of AI-based modelling can be also applied by linking the characteristics of nanocarriers and effects in the body. It is this integration of AI and model-based drug development that consequently promotes the rational development of nanoparticles and may aid in enhancing and accelerating the development of targeted delivery system development with improved clinical success rates[47].

6.2 Stimuli-Responsive and Smart Delivery Systems

The smart drug delivery systems and stimuli-responsive systems are meant to release therapeutics in the event of a biological or external stimulus (pH, enzymes, temperature or ultrasound). These systems have precise spatial and temporal control of drug release, and hence they can be highly used in local therapy of complex body parts. Artificial intelligence is one of the keys to the improvement of trigger sensitivity and responsiveness by means of analysis of massive datasets, which give the correlation of material properties, environmental conditions and release behavior. AI-powered decision-making devices can be employed to aid in the selection of the most effective trigger mechanisms and material compositions that have the least off-target effects on the therapeutic activity. Predictive tuning of smart delivery systems based on contexts of the disease and patient groups can be done using these methods[48]. By introducing AI-aided decision-making processes to the development of a formulation, pharmaceutical scientists will be able to compare numerous design scenarios systematically and select the most appropriate smart delivery approaches, enhancing the strengths and reproducibility of targeted drug delivery platforms, as demonstrated in Figure 6.



Figure 6: AI-Driven Workflow for the Design and Optimization of Stimuli-Responsive and Smart Drug Delivery Systems.

6.3 Implantable and Localized Drug Delivery Devices

The implantable and localized drug delivery devices provide sustained therapy and site specific therapy by the maintenance of the concentration of the therapeutic drug at the target site over a long period. The controlled-release implants are most useful in the treatment of chronic diseases, oncology, and in regenerative medicine since in these cases, long-term local therapy is required. Optimization of geometry, material distribution and drug distribution of implants can be done with the use of computational modelling and artificial intelligence to achieve the desired release pattern. The integration of AI and model-informed drug development techniques will allow simulating the release kinetics in varying physiological states that will be applied in designing rational implants and optimization of drug doses. These prediction tools will reduce development process time wastage and improve predictability as they can be used to establish the most optimal settings before clinical evaluation. Personalized exposure to AI-drugs and computational modelling can result in improved control of localized doses, decreased systemic toxicity and bench-to-bedside translation of implantable delivery systems in a more efficient and scientifically-driven manner.

7. Surgical-Assisted Therapeutic Applications

7.1 Image-Guided Drug Delivery in Surgical Settings

Image based delivery is a practice in surgery to precisely instil therapeutic agents into anatomically precise sites. The intraoperative imaging modalities available to facilitate real-time tissue, surgical margin, and delivery devices visualisation and reduce off-target exposure are MRI, CT, ultrasound and fluorescence imaging. These techniques are particularly applicable to localized therapies where the space is directly influenced by appropriate space control that has a direct effect on treatment effectiveness. Precision of therapeutic effects is also enhanced by live tracking of drug discharge since it allows clinicians to assess the distribution and retention during surgery. Regarding the pharmaceutical aspect, image-guided delivery supports the delivery of drugs in control and targeted manner, in such a way that more complex surgical conditions are best addressed with advanced drug delivery systems[49].

7.2 AI-Assisted Surgical Planning for Local Drug Delivery

The localized drug delivery towards surgical planning has been proposed as a valuable input of the artificial intelligence that could be applied in surgical planning to give data-driven navigation and decision support. The AI-driven systems analyze preoperative imaging and anatomy data to assist with the identification of the most optimal locations of delivery and routes. These technology devices will enhance accuracy during injectable depot/ implants or catheter-delivery systems insertion. Also, robot-based platforms contribute to reproducibility and accuracy particularly in the minimally invasive surgeries requiring high spatial accuracy. The prediction and the ability to make surgical plans more patient-centered through the combination of AI and anatomical modeling will enable the safe and effective application of the controlled delivery of drugs into the human body to clinical practice[50].

7.3 Intraoperative and Post-Surgical Drug Delivery Strategies

The strategies of intraoperative and post-surgical drug delivery are used to maintain the treatment levels at the target site and avoid exposure to the systemic environment. The delivery of the localised chemotherapy during the operation process allows high concentrations of the drugs which are concentrated in the peripheral areas of the tumours, thus increasing the effectiveness with reduced side effects. Similarly, local use of anti-inflammatory and antimicrobial agents are used in the healing of wounds and prevention of postoperative infection. The commonly employed ways to sustain drug action are controlled release

formulations, implants and injectable depots that are employed following surgery. The approaches stress the significance of pharmaceutics in the long-term effect of the surgical outcome due to the use of directed, manageable and location-specific technologies of drug delivery.

9. Regulatory, Ethical, and Practical Considerations

The Artificial intelligence has been a major control, ethics and practice in the design and therapy choice process of drug delivery systems. One of the most important issues is the validation and interpretability of AI models. The decisions made regarding drug delivery based on AI must be concise and should be explanatory and must be scientifically backed in order to pass the review and supervision of the clinics. Despite their strength, Black-box models are alarming when predicting is not readily revealed in any biological or pharmacokinetic concept, particularly in extreme risk therapeutic settings.

The regulatory policies of the AI-driven drug delivery systems are still at the developmental phase, as the existing regulations were developed concerning the field with references primarily to the traditional pharmaceutical and medical equipment domain. The software is typically part of an AI-based application that can incorporate the modules of imaging and delivery and can be complex in classification and approval naming. An ever-growing pressure on the necessity to ensure consistency in performance in terms of how to deal with the populations and use conditions is mounting on the regulating bodies in the process of validating the models and the lifecycle management and post-deployment surveillance.

There are also ethical concerns of utilizing patient data to develop and train AI models. The data privacy, the informed consent, and the fair representation of the different populations should be followed in order to prevent the appearance of biased decision-making. The formulation scientists, clinicians, data scientists and regulators also require various interdisciplinary work in the practical application. Such regulatory and ethics concerns are emergent as far as commercialization of AI-powered drug delivery systems is concerned, which have been tested in sites to safe, effective and generally acceptable clinical practices.

10. Limitations and Challenges

In spite of the rapid progress in AI and computational modelling, these technologies have several limitations in application, which are impeding their widespread application to drug delivery studies. One of these issues is data scarcity, particularly of quality, which involves combination of parameters of formulations, anatomy, pharmacokinetics, and clinical outcomes. Lack of cohesive data sources and non- standardized reporting needs in model training renders it less predictive and reliable. The fact that the experimental protocols have not been standardized also makes it difficult to reuse and compare the datasets across studies.

Model generalizability is also another critical concern. It is due to the trained AI models which are trained on a particular population, type of illness or a delivery system might not be valid in other groups of patients or other ailments. Biological variability, heterogeneity of diseases, and variation in clinical practice are also examples of factors, which may introduce significant variation in the performance of the model. One needs to ensure that it is strong in a large range of populations, which may be difficult to acquire in the form of validation and representative training data.

The barriers to the successful practice are also present in the context of the AI tools integration into the clinical workflow. The lack of technical education, the disruption of the work process, or the lack of understanding of the liability is one of the potential obstacles to AI-guided delivery systems implementation among clinicians. Other than that, computational outcomes must be presented in a way that is clinically relevant and easy to make decisions rather than present it in a hefty manner to the users. These problems will be solved in the number of improved data infrastructure, interdisciplinary education and regarding in particular the correlation of AI tools with clinical and pharmaceutical reality.

11. Future Perspectives

The future of targeted drug delivery can potentially be artificial intelligence, anatomical modelling and precision pharmaceutics convergence. As the computational tools are developed, AI will be in a position to abandon the retrospective prediction phase and move to the advanced stage of proactive design of the delivery systems that should be capable of adapting to the particular anatomy of the patient and the development of the disease. Imagings live, physiological and predictive modeling will be incorporated, and it will be possible to exercise even more control over drug localization and release.

There will be an inclination towards individualized systems of drug delivery as the characteristic feature of the next-generation therapeutics. Artificial intelligence-based platforms may be utilized to personalize formulation composition, dose schedule and route of administration to individual patients based on anatomia, pharmacokinetic reaction and treatment goals. This may increase the efficacy and minimise the side effects particularly in complex diseases such as cancer and neurological disorders. More in the future, an autonomous and adaptable platform of therapeutic delivery can be fabricated that will be capable of reacting to the dynamic biological signals or imaging feedback, modifying the rate at which a drug is introduced. The systems would also be in a position to automatically optimize therapy and it would be a paradigm shift in the way treatment is delivered. The, further, continuation of the development of the computational modeling, regulatory science, and interdisciplinary cooperation will be instrumental enough to transform this vision into reality, and ensure that the future drug delivery

technologies are innovative, not only, but also, clinically responsible.

12. Conclusion

The targeted drug delivery age is being reformed to include artificial intelligence and computational modelling to enable data-driven and anatomy-conscious precision-oriented therapeutic design. The invention of machine learning, multiscale modelling, and imaging fusion has not only improved the understanding of the distribution, release and therapeutic performance of intricate biological surroundings to a significant extent. These technologies have enhanced the capability of modern pharmaceutics that allows rational design of nanocarriers, intelligent delivery systems, and focal therapeutic platforms. Incorporating the efforts of formulation science and anatomical and physiological knowledge, AI-based approaches reduce the number of trials and errors and enhance the pace of bench-to-bedside translation. The implementation of computational intelligence into the surgical-assisted and image-guided delivery plans is also another step towards better spatial accuracy and therapeutic control. As the data quality, regulation and clinical integration issues remain, there are some on-going interdisciplinary efforts that continue to break these barriers down. Altogether, AI, computational modeling, and anatomy-driven design are a solid base of the next-generation drug delivery systems that introduce new opportunities of offering personalized, effective and safer therapeutic intervention.

References

1. Panchpuri M, Painuli R, Kumar C. Artificial intelligence in smart drug delivery systems: a step toward personalized medicine. RSC Pharmaceutics. 2025.
2. Mahdi WA, Alhowyan A, Obaidullah AJ. Intelligence analysis of drug nanoparticles delivery efficiency to cancer tumor sites using machine learning models. Scientific Reports. 2025 Jan 6;15(1):1017.
3. Bhatia N, Malik P, Sampathi S. Characterization Tools for current drug delivery systems. InBiosystems, Biomedical & Drug Delivery Systems: Characterization, Restoration and Optimization 2024 Jun 14 (pp. 11-42). Singapore: Springer Nature Singapore.
4. López EM, Espinal JA, Aguirre AP, Martínez SV, Navarro AF, Barreto PM. Evaluación experimental de nanopartículas como vehículos de administración controlada de fármacos: resultados preliminares in vitro. Educational Regent Multidisciplinary Journal. 2025 Jul 25;2(4):1-26.
5. Jahandoost A, Dashti R, Houshmand M, Hosseini SA. Utilizing machine learning and molecular dynamics for enhanced drug delivery in nanoparticle systems. Scientific Reports. 2024 Nov 4;14(1):26677.
6. AlOmari AK, Almansour K. Chemometric and computational modeling of polysaccharide coated drugs for colonic drug delivery. Scientific Reports. 2025 Apr 26;15(1):14694.
7. Abdalla, Y., McCoubrey, L. E., Ferraro, F., Sonnleitner, L. M., Guinet, Y., Siepmann, F., ... & Shorthouse, D. (2024). Machine learning of Raman spectra predicts drug release from polysaccharide coatings for targeted colonic delivery. *Journal of Controlled Release*, *374*, 103-111.
8. Heredia NS, Vizuete K, Flores-Calero M, Pazmiño V K, Pilaquinga F, Kumar B, Debut A. Comparative statistical analysis of the release kinetics models for nanoprecipitated drug delivery systems based on poly (lactic-co-glycolic acid). PLoS One. 2022 Mar 10;17(3):e0264825.
9. Mares AG, Pacassoni G, Marti JS, Pujals S, Albertazzi L. Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology. PLoS One. 2021 Jun 18;16(6):e0251821.
10. Cengiz NA, Kabasakal H, Kurt R, Erik M, Maran FN, Türk İ. Artificial Intelligence Integration in Nanobionic Systems: New Approaches for Toxicology and Medical Applications. International Journal of Boron Science and Nanotechnology. 2025 Dec 12;1(4):34-61.
11. Jiang Z, Zhang M, Li P, Wang Y, Fu Q. Nanomaterial-based CT contrast agents and their applications in image-guided therapy. Theranostics. 2023 Jan 1;13(2):483.
12. Han Y, Kim DH, Pack SP. Nanomaterials in drug delivery: Leveraging artificial intelligence and big data for predictive design. International Journal of Molecular Sciences. 2025 Nov 17;26(22):11121.
13. Omidian H, Wilson RL. PLGA Implants for Controlled Drug Delivery and Regenerative Medicine: Advances, Challenges, and Clinical Potential. Pharmaceuticals. 2025 Apr 27;18(5):631.
14. Yao W, Lin Y, Weng Y, Wu Y, Zheng L, Zheng D, Xi Q, Zhao J. Lipid-based nanoparticles in cancer therapy: advances in targeted drug delivery and therapeutic potential for renal cell carcinoma. Advanced Science. 2025 Sep;12(36):e07666.
15. Sabín J, Santisteban-Veiga A, Costa-Santos A, Abelenda Ó, Domínguez-Arca V. Liposomes as “Trojan Horses” in Cancer Treatment: Design, Development, and Clinical Applications. Lipidology. 2025 Dec 8;2(4):25.
16. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, Ramirez BI, Sánchez-Guirales SA, Simon JA, Tomietto G, Rapti C. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics. 2024 Oct 14;16(10):1328.
17. Arav Y. Advances in modeling approaches for oral drug delivery: artificial intelligence, physiologically-based pharmacokinetics, and first-principles models. Pharmaceutics. 2024 Jul 24;16(8):978.

18. Dennahy IS, Han Z, MacCuaig WM, Chalfant HM, Condacse A, Hagood JM, Claros-Sorto JC, Razaq W, Holter-Chakrabarty J, Squires R, Edil BH. Nanotheranostics for image-guided cancer treatment. Pharmaceutics. 2022 Apr 22;14(5):917.

19. Łopuszyńska N, Węglarz WP. Contrasting Properties of polymeric nanocarriers for mri-guided drug delivery. Nanomaterials. 2023 Jul 25;13(15):2163.

20. Smolak B, Dynarowicz K, Bartusik-Aebisher D, Henrykowska G, Aebisher D, Guz W. Combining Fluorescence and Magnetic Resonance Imaging in Drug Discovery—A Review. Pharmaceuticals. 2025 Dec 26;19(1):56.

21. Lankoff AM, Czerwińska M, Kruszewski M. Advances in nanotheranostic systems for concurrent cancer imaging and therapy: An overview of the last 5 years. Molecules. 2024 Dec 19;29(24):5985.

22. Acter S, Ngema LM, Moreau M, China D, Viswanathan A, Ding K, Choonara YE, Yasmin-Karim S, Ngwa W. PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System. Pharmaceutics. 2024 Nov 20;16(11):1481.

23. Li M, Li T, Wu F, Ren F, Xue S, Li C. Advanced NIR-II fluorescence imaging technology for precise evaluation of nanomedicine delivery in cancer therapy. Chemosensors. 2024 Jun 16;12(6):113.

24. Hong S, Jiao Y, Li R, Lei P, Dong C, Guo S, Shuang S. β-Cyclodextrin-Grafted Polypyrrole–Rhodamine B Nanoplatforms for Drug Delivery and Image-Guided Photothermal Therapy In Vitro. Materials. 2025 Nov 25;18(23):5313.

25. Razek A. Image-guided surgical and pharmacotherapeutic routines as part of diligent medical treatment. Applied Sciences. 2023 Dec 6;13(24):13039.

26. Razek A. Image-guided surgical and pharmacotherapeutic routines as part of diligent medical treatment. Applied Sciences. 2023 Dec 6;13(24):13039.

27. Friebe M, Illanes A. Advancements in medical imaging and image-guided procedures: A potential—or rather likely—paradigm shift in diagnosis and therapy: Understand disruption and take advantage of it!. Applied Sciences. 2023 Aug 14;13(16):9218.

28. Das KP. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. Frontiers in Medical Technology. 2023 Jan 6;4:1067144.

29. Buchete NV, Cicha I, Dutta S, Neofytou P. Multiscale physics-based in silico modelling of nanocarrier-assisted intravascular drug delivery. Frontiers in Drug Delivery. 2024 Mar 4;4:1362660.

30. Muzard C, Seguin J, Bonnefoy J, Salkini N, Serra V, Alhareth K, Lemdani K, Mignet N. Pre-clinical evaluation of mRNA-lipid nanoparticles' potency and toxicity: current practices and future directions. In vitro models. 2025 Nov 24:1-8.

31. Leporace M, Calabria FF, Siciliano R, Capalbo C, Filippiadis DK, Iezzi R. The thermal ablation with MRgFUS: from physics to oncological applications. Cancers. 2024 Dec 26;17(1):36.

32. Conti A, Kamimura HA, Novell A, Duggento A, Toschi N. Magnetic resonance methods for focused ultrasound-induced blood-brain barrier opening. Frontiers in Physics. 2020 Sep 30;8:547674.

33. Moreau M, Richards G, Yasmin-Karim S, Narang A, Deville Jr C, Ngwa W. A liquid immunogenic fiducial eluter for image-guided radiotherapy. Frontiers in Oncology. 2022 Dec 21;12:1020088.

34. Li P, Yang Z, Jiang S. Needle-tissue interactive mechanism and steering control in image-guided robot-assisted minimally invasive surgery: a review. Medical & Biological Engineering & Computing. 2018 Jun;56(6):931-49.

35. Verma R, Minocha N, Mittal V, Kaushik D. Exploring the Potential of Nano Drug Delivery Systems in Non-small Cell Lung Cancer Treatment: Recent Developments and Perspectives. Current Drug Therapy. 2025 Apr;20(3):280-97.

36. Prakashan D, Pr R, Kaushik A, Gandhi S. Sustainable nanotechnology and artificial intelligence to empower Image-Guided therapy for precision healthcare. BME frontiers. 2025 Jul 17;6:0150.

37. Jin Z, Chang J, Dou P, Jin S, Jiao M, Tang H, Jiang W, Ren W, Zheng S. Tumor targeted multifunctional magnetic nanobubbles for MR/US dual imaging and focused ultrasound triggered drug delivery. Frontiers in bioengineering and biotechnology. 2020 Dec 7;8:586874.

38. Zhou L, Bak A, Hyodo K, Abrahamsson B. Introducing the Molecular Pharmaceutics Special Issue on Industrial Drug Delivery─ In Silico to Bedside. Molecular Pharmaceutics. 2023 Oct 2;20(10):4797-9.

39. Alshahrani SM, Alotaibi HF, Alqarni M. Modeling and validation of drug release kinetics using hybrid method for prediction of drug efficiency and novel formulations. Frontiers in Chemistry. 2024 Jun 21;12:1395359.

40. Song W, Muhammad S, Dang S, Ou X, Fang X, Zhang Y, Huang L, Guo B, Du X. The state-of-art polyurethane nanoparticles for drug delivery applications. Frontiers in Chemistry. 2024 Feb 26;12:1378324.

41. Kasimieh O, Ahmed MM, Othman ZK, Ali I, Hassan MM, Maulion PM, Babalola AE, Okesanya OJ, Ukoaka BM, Branda F, Lucero-Prisno III DE. Deep learning in real-time image-guided surgery: a systematic review of applications, methodologies, and clinical relevance. Artificial Intelligence Surgery. 2025 Dec 16;5(4):557-71.

42. Ferreira JA, de Oliveira P, da Silva PM, Grassi M. From life-saving to life-threatening: A mathematical model to simulate bacterial infections in surgical procedures. SIAM Journal on Applied Mathematics. 2021;81(3):1226-47.

43. Seyedhamzeh M, Houshmandyar S, Hamidi M. Smart drug delivery systems: Technological advancements, clinical challenges, and future

perspectives. Nanoscale and Advanced Materials. 2025 Aug 1;2(2):121-36.

44. Huang W, Wang X, Chen Y, Yu C, Zhang S. Advancing drug-drug interactions research: integrating AI-powered prediction, vulnerable populations, and regulatory insights. Frontiers in Pharmacology. 2025 Aug 13;16:1618701.

45. Oualikene-Gonin W, Jaulent MC, Thierry JP, Oliveira-Martins S, Belgodère L, Maison P, Ankri J, Scientific Advisory Board of ANSM. Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities. Frontiers in pharmacology. 2024 Aug 2;15:1437167.

46. Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y, Xi J, Tao L, Wang J, Du L, Chen G. The role of artificial intelligence in drug screening, drug design, and clinical trials. Frontiers in Pharmacology. 2024 Nov 29;15:1459954.

47. Raman K, Kumar R, Musante CJ, Madhavan S. Integrating Model-Informed Drug Development With AI: A Synergistic Approach to Accelerating Pharmaceutical Innovation. Clinical and Translational Science. 2025 Jan;18(1):e70124.

48. Yingngam B, Navabhatra A, Sillapapibool P. AI-driven decision-making applications in pharmaceutical sciences. InUsing Traditional Design Methods to Enhance AI-Driven Decision Making 2024 (pp. 1-63). IGI Global Scientific Publishing.

49. Niazi SK. Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes. Pharmaceuticals. 2025 Aug 26;18(9):1271.

50. Visan AI, Negut I. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. Life. 2024 Feb 7;14(2):233.